"As STMicroelectronics continues to grow, we are looking for ways to enhance our core business processes," said Jack Dauber, Vice President and Corporate Marketing Director at STMicroelectronics. "Model N's Revenue Management platform with industry specific applications will be a catalyst for delivering innovative solutions to our business partners and facilitate the implementation of our global strategy by providing better analytical and decision making process tools."

Purpose built for the unique needs of semiconductor and component manufacturers, the integrated Model N High Tech Revenue Management Suite links the entire transactional revenue life cycle, from opportunity and design tracking, to pricing and quoting, through channels incentive management and reconciling ship and debit data with POS. The product provides unique capabilities for self-service design registration and interactive quoting tied to a powerful rules-based pricing engine. These capabilities not only improve the flexibility and accuracy of pricing for manufacturers, but also reduce quote turnaround time from days to minutes -- significantly improving deal conversion rates.

"STMicroelectronics' commitment to Model N is another indicator that in an increasingly global semiconductor industry, improving core revenue management processes is a universal need," said Richard Fitchen, High Tech General Manager at Model N. "STMicroelectronics and other industry leaders understand the positive impact that Revenue Management best practices can have on building and maintaining lucrative channel relationships, and are augmenting their legacy ERP and CRM systems with a Model N Revenue Management solution specifically designed for the complexities of their global direct and channel business. We look forward to partnering with them and delivering solutions that fuel the growth of their eco-system."

Following Model N's investments in the past year in a global company infrastructure and operational focus, the agreement with STMicroelectronics also represents another customer recognition that Model N operates globally and with a local reach across North America, Europe, and Asia.

"Our partnership with STMicroelectronics represents an important validation of our growing capabilities to serve large global organizations," said Niels Skov, Managing Director Europe for Model N. "We look forward to collaborating with them and raising the bar further for revenue management solutions in the High Tech industry."

STMicroelectronics will implement Model N's Global Price Management, Deal Management, Deal Analytics, and Channel Revenue Management solutions.

About Model N

Model N is a leader in Revenue Management solutions, offering an integrated suite of applications for analytics, pricing strategy and execution, contracts, compliance, and settlements optimized for the industry practices of High Tech and Life Science companies. Enabling the creation of a seamless, end-to-end process from price setting through settlements payment, Model N's uniquely integrated approach eliminates revenue leakage and delivers the visibility and controls needed to avoid the risks of non-compliance to government reporting regulations such as Sarbanes-Oxley and government pricing requirements. Customers include: Boston Scientific Corporation; Bristol-Myers Squibb Company; Cypress Semiconductor Corporation; Intersil Corporation; Linear Technology Corporation; Medtronic, Inc.; Microchip Technology, Inc.; Micron Technology Inc.; Ortho-Clinical Diagnostics, a Johnson & Johnson company; ON Semiconductor, Inc. and Pfizer, Inc. Model N is located in Redwood Shores, California. For additional information, visit www.modeln.com.

Model N is a mark of Model N, Inc. All other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.

Media Contact: Sean Cassidy Model N, Inc. Tel: +1 650-610-4820 scassidy@modeln.com

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

SOURCE: Model N, Inc.

Purpose built for the unique needs of semiconductor and component manufacturers, the integrated Model N High Tech Revenue Management Suite links the entire transactional revenue life cycle, from opportunity and design tracking, to pricing and quoting, through channels incentive management and reconciling ship and debit data with POS. The product provides unique capabilities for self-service design registration and interactive quoting tied to a powerful rules-based pricing engine. These capabilities not only improve the flexibility and accuracy of pricing for manufacturers, but also reduce quote turnaround time from days to minutes -- significantly improving deal conversion rates.

"STMicroelectronics' commitment to Model N is another indicator that in an increasingly global semiconductor industry, improving core revenue management processes is a universal need," said Richard Fitchen, High Tech General Manager at Model N. "STMicroelectronics and other industry leaders understand the positive impact that Revenue Management best practices can have on building and maintaining lucrative channel relationships, and are augmenting their legacy ERP and CRM systems with a Model N Revenue Management solution specifically designed for the complexities of their global direct and channel business. We look forward to partnering with them and delivering solutions that fuel the growth of their eco-system."

Following Model N's investments in the past year in a global company infrastructure and operational focus, the agreement with STMicroelectronics also represents another customer recognition that Model N operates globally and with a local reach across North America, Europe, and Asia.

"Our partnership with STMicroelectronics represents an important validation of our growing capabilities to serve large global organizations," said Niels Skov, Managing Director Europe for Model N. "We look forward to collaborating with them and raising the bar further for revenue management solutions in the High Tech industry."

STMicroelectronics will implement Model N's Global Price Management, Deal Management, Deal Analytics, and Channel Revenue Management solutions.

About Model N

Model N is a leader in Revenue Management solutions, offering an integrated suite of applications for analytics, pricing strategy and execution, contracts, compliance, and settlements optimized for the industry practices of High Tech and Life Science companies. Enabling the creation of a seamless, end-to-end process from price setting through settlements payment, Model N's uniquely integrated approach eliminates revenue leakage and delivers the visibility and controls needed to avoid the risks of non-compliance to government reporting regulations such as Sarbanes-Oxley and government pricing requirements. Customers include: Boston Scientific Corporation; Bristol-Myers Squibb Company; Cypress Semiconductor Corporation; Intersil Corporation; Linear Technology Corporation; Medtronic, Inc.; Microchip Technology, Inc.; Micron Technology Inc.; Ortho-Clinical Diagnostics, a Johnson & Johnson company; ON Semiconductor, Inc. and Pfizer, Inc. Model N is located in Redwood Shores, California. For additional information, visit www.modeln.com.

Model N is a mark of Model N, Inc. All other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.

Media Contact:
Sean Cassidy
Model N, Inc.
Tel: +1 650-610-4820
Email Contact

SOURCE: Model N, Inc.

http://www2.marketwire.com/mw/emailprcntct?id=3094330C690548AF

Non S&P 500 - Weekly

Non S&P 500 - Day Ahead

ConferenceCall/Webcast - Weekly ConferenceCall/Webcast - Day

Meetings - Weekly

S&P 500 Earnings - Monthly

Economic Indicators

IPO events

Dividends

Daily earnings hits & misses

Federal Reserve events

MEETINGS

DATE GMT SYMBOL EVENT TITLE 13 Nov

Accuray Incorporated Annual Stockholder Meeting 13 Nov 16:45

Acme Packet, Inc. at Needham & Co. Telecom Tech Day 13 Nov 23:30

Akorn, Inc. at Credit Suisse Group Healthcare Conf 13 Nov 17:00

Alexion Pharma.s at Credit Suisse Group Healthcare Conf 13 Nov 12:10

Alliance Financial at Sandler O'Neill&Partners Conf 13 Nov 21:00

AMERIGROUP Corp. at Credit Suisse Group Healthcare Conf 13 Nov 13:00

Anadarko Petroleum at Bank of America Conf 13 Nov 15:40

Apache Corp. at Bank of America Securities Energy Conf 13 Nov 17:30

ARRIS Group, Inc. at Needham & Co. Telecom Tech Day Conf

13 Nov 18:00

Artes Medical, Inc. Shareholders Meeting 13 Nov 15:55

Astoria Financial at Sandler O'Neill&Partners Conf 13 Nov 14:20

Atmos Energy at Bank of America Conf 13 Nov 15:00

Baker Hughes at Bank of America Conf 13 Nov 16:30

Bancorp Rhode Island at Sandler O'Neill&Partners Conf 13 Nov 19:10

BancorpSouth, at Sandler O'Neill&Partners Conf 13 Nov 3:55

Bank of NewYrk Mellon at Financial TimesCIS (Asia) Forum 13 Nov 12:45

Bank of Smithtown at Sandler O'Neill&Partners Conf 13 Nov 18:30

Barr Pharma.s, at Credit Suisse Group Healthcare Conf

13 Nov 14:20

Basic Energy Services, at Bank of America Conf 13 Nov 16:30

Berkshire Hills Bancorp at Sandler O'Neill&Partners Conf

13 Nov 19:30

Bill Barrett at Bank of America Conf 13 Nov 23:30

Bio-Reference Laboratories at Credit Suisse Grp Conf 13 Nov 19:10

Boston Scientific at Sandler O'Neill&Partners Conf 13 Nov 18:10

BRIGHAM EXPLORATION CO at Bank of America Conf 13 Nov 20:10

Cabot Oil & Gas at Bank of America Conf 13 Nov 20:50

Cal Dive Intl. at Bank of America Securities Energy Conf 13 Nov 21:05

Capital City Bank Group at Sandler O'Neill&Partners Conf

13 Nov 15:55

CapitalSource Inc at Sandler O'Neill&Partners Conf 13 Nov 19:10

Cardinal Financial at Sandler O'Neill&Partners Conf 13 Nov 16:00

Centene Corp. at Credit Suisse Group Healthcare Conf 13 Nov 19:00

Chemed Corp. at Credit Suisse Group Healthcare Conf 13 Nov 20:10

Cheniere Energy at Bank of America Securities Energy Conf 13 Nov 18:00

Cisco Systems Annual Shareholders Meeting 13 Nov 18:00

Citigroup at Sandler O'Neill&Partners Conf 13 Nov 12:45

Comerica at Sandler O'Neill&Partners Conf 13 Nov 14:45

Community Trust at Sandler O'Neill&Partners Conf 13 Nov 15:00

CONCHO RES INC at Bank of America Securities Energy Conf 13 Nov 20:45

Concurrent Computer at Needham&Co. TechDay Conf 13 Nov 13:40

Continental Resources, at Bank of America Conf 13 Nov 18:30

Covance at Credit Suisse Group Healthcare Conf 13 Nov 18:30

Credit Suisse Group Healthcare Conf 13 Nov 17:30

Cytokinetics, Inc. at Credit Suisse Group Healthcare Conf 13 Nov 15:00

DeVry Shareholders Meeting 13 Nov 21:00

Dyax Corp. at Credit Suisse Group Healthcare Conf 13 Nov 14:00

Electronic Arts at BMO Capital Markets Conf 13 Nov 19:55

ENCORE BANCSHARES INC at Sandler O'Neill&Partners Conf 13 Nov 17:30

Ensco Intl. at Bank of America Securities Energy Conf

13 Nov 14:20

EOG Resources, at Bank of America Conf 13 Nov 17:00

Eric May Luncheons 13 Nov 16:00

Express Scripts, at Credit Suisse Group Healthcare Conf 13 Nov 19:55

F.N.B. at Sandler O'Neill&Partners Conf 13 Nov 13:20

Fifth Third Bancorp at Sandler O'Neill&Partners Conf 13 Nov 14:45

First Financial Ohio at Sandler O'Neill&Partners Conf 13 Nov 19:55

First Financial Hldngs at Sandler O'Neill&Partners Conf 13 Nov 13:00

First Horizon National at Merrill Lynch Conf 13 Nov 18:00

First Midwest Bancorp at Sandler O'Neill&Partners Conf 13 Nov 19:10

First Niagara Financial at Sandler O'Neill&Partners Conf

13 Nov 21:40

First Place Financial at Sandler O'Neill&Partners Conf 13 Nov 12:10

FirstMerit at Sandler O'Neill&Partners Conf 13 Nov 12:10

Flushing Financial at Sandler O'Neill&Partners Conf 13 Nov 20:50

Fmc Tech., Inc. at Bank of America Securities Energy Conf 13 Nov 13:30

FTI Consulting at Argyle Executive Ldrshp Forum 13 Nov 16:00

G&K Services Shareholders Meeting 13 Nov 15:00

Genentech, Inc. at Credit Suisse Group Healthcare Conf 13 Nov 18:50

GeoMet, Inc at Bank of America Securities Energy Conf 13 Nov 14:30

GLU MOBILE INC at BMO Capital Markets Conf 13 Nov 3:15

Google at Piper Jaffray Global Internet Summit 13 Nov 20:10

GulfMark Offshore at Bank of America Conf 13 Nov 21:05

Hancock Hldng Co. at Sandler O'Neill&Partners Conf 13 Nov 19:15

Harmonic at Needham & Co. Telecom Tech Day Conf 13 Nov 21:30

Healthways at Credit Suisse Group Healthcare Conf 13 Nov 17:30

Hornbeck Offshore Services, at Bank of America Conf 13 Nov 13:50

ICF Intl. at SMi Grp Financial Modelling in Oil&Gas Conf

13 Nov 18:30

IdentiPHI Invstr Roundtable Meetgs for Shrhldrs-Chicago 13 Nov 8:05

Intel Corp. at DisplaySearch Taiwan TV Supply Chain Conf

13 Nov 19:00

Intl. Game Tech. at BMO Capital Markets Conf 13 Nov 8:30

Intersil at DisplaySearch Taiwan TV Supply Chain Conf 13 Nov 17:30

Johnson & Johnson at Credit Suisse Group Healthcare Conf 13 Nov 18:20

KOHLBERG CAPITAL CORP at Argyle Executive Ldrshp Forum 13 Nov 22:00

Laboratory of America at Credit Suisse Global Conf 13 Nov 16:30

LifePoint Hospitals, at Credit Suisse Grp Conf 13 Nov 14:30

Magellan Health Services at Credit Suisse Grp Conf 13 Nov 14:00

Marsh & McLennan at Standard&Poors Bermuda Conf 13 Nov 14:40

Marshall & Ilsley at Merrill Lynch Conf 13 Nov 21:00

MB Financial at Sandler O'Neill&Partners Conf COPYRIGHT

Copyright Thomson Reuters 2008. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.

MMMM

"Although only introduced in 2003, drug eluting stents have reshaped the entire cardiovascular industry in just a few short years," says Frost & Sullivan Research Analyst Archana Swathy. "These devices are taking percutaneous coronary intervention to new heights, addressing many of the concerns and issues restricting the availability of care in the past."

Data surrounding potential safety risks associated with DES and possible late stent thrombosis had resulted in lower usage in late 2006-07. Recognizing the importance of clinical data, Boston Scientific addressed the need of physicians for additional DES safety information and continues to provide effective data that reinforce its leadership position in the DES arena. Earlier this year, Boston Scientific reported encouraging one-year data from the SYNTAX trial that compared percutaneous coronary intervention (PCI) using the TAXUS Express2 paclitaxel-eluting coronary stent system to contemporary coronary artery bypass graft surgery (CABG). The TAXUS stent systems have been evaluated by the industry's most extensive randomized, controlled clinical trial program, supplemented by data on more than 35,000 patients enrolled in post-approval registries. To date, approximately 4.6 million TAXUS stents have been implanted globally, making them the world's most frequently used drug-eluting stents.

In addition to its intense focus on evidence-based medicine and a robust clinical trial program, Boston Scientific has introduced the Stentplus(TM) program to enhance patient outcomes post PCI by improving patient compliance with physician-prescribed, dual anti-platelet therapy. This comprehensive program specifically targets DES patients, regardless of the stent brand.

It is endorsed by several prominent organizations, including the Society for Cardiovascular Angiography and Interventions (SCAI), and is used by nearly 1,000 hospitals and more than 160,000 patients nationwide.

Frost & Sullivan recognizes Boston Scientific's unique capacity to establish and sustain its leadership in this highly competitive environment, and has selected the company to be the recipient of its 2008 North American Market Leadership Award for the Drug Eluting Stents Market.

Each year, Frost & Sullivan presents this award to the company that has demonstrated market share leadership through the implementation of sound market strategy. The recipient has displayed excellence in all areas of the market leadership process including the identification of market challenges, drivers, and restraints, as well as strategy development and methods of addressing these market dynamics.

Frost & Sullivan's Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership(TM) empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnership Services, visit http://www.awards.frost.com.

     Contact:
     Jake Wengroff
     210.247.3806
     jake.wengroff@frost.com

SOURCE Frost & Sullivan

http://www.frost.com